Reading AIM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIM free→Reading AIM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AIM free→QuarterlyIQ Insights · AIM
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189…
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 20, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 7,519,351 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.325…
Unregistered Sales of Equity Securities. The information set forth in
Entry into a Material Definitive Agreement. As previously disclosed, AIM ImmunoTech Inc. (the “Company”) previously issued to Streeterville Capital, LLC (the “Lender”) a Promissory Note in the original principal amount of $3,301,250.00 dated February 16, 2024 (the “Note”) pursuant to a Note Purchase Agreement between the Company and the Lender. The Company and the Lender subsequently extended the maturity date of the Note to June 30, 2026. On May 18, 2026, the Company and the Lender entered i…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
to the extent required. The information, including Exhibit 99.1, referenced in this Item 2.02, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if and to the extent such subsequent filing specif…
Unregistered Sales of Equity Securities. As previously reported, AIM ImmunoTech Inc. (the “Company”) entered into that certain warrant exercise inducement offer letter agreement, dated May 7, 2026 (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B warrants to purchase common stock, par value $0.001 per share (the “Common Stock”), of the Company, issued on May 31, 2024; (ii) Class C and Class D Common Stock purchase warrants issued on September 30, 2024; and (iii…
Unregistered Sales of Equity Securities. The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2). Neither the Inducement Warrants nor the Inducement Warrant Shares have been registered under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securiti…
Entry into a Material Definitive Agreement. On May 7, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024 (the “Existing May 2024 Warrants”), exercisable for up to an aggregate of 112,819 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) Class C and Class D Commo…
Entry into a Material Definitive Agreement. On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market pub…
Entry into a Material Definitive Agreement. Warrant Agency Agreement On March 6, 2026, in connection with the closing of its previously announced Rights Offering (defined below), AIM ImmunoTech Inc. (the “ Company ”) entered into a Warrant Agency Agreement with Equiniti Trust Company, LLC (“ EQ ”), pursuant to which EQ agreed to act as warrant agent with respect to warrants included in the units issued by the Company in the Rights Offering. A copy of the Warrant Agency Agreement is filed as E…
Other Events. On March 6, 2026, the Company completed its previously announced rights offering (the “ Rights Offering ”) pursuant to its effective registration statement on Form S-1, as amended (Registration No. 333-292085), previously filed with and declared effective by the Securities and Exchange Commission (the “ SEC ”), a prospectus and a prospectus supplement filed with the SEC. Pursuant to the Rights Offering, the Company sold an aggregate of 1,842 units consisting of an aggregate of 1…
Material Modification to Rights of Security Holders. The disclosure contained in
Other Events. A Phase I/II Open Label Study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in pancreatic cancer patients with stable disease Post-FOLFIRINOX is being conducted. Attached hereto as Exhibit 99.2 is an interim clinical progress update for this study which is incorporated by reference herein. Please see Exhibit 99.2 for more detailed information. Cautionary Statement Regarding Forward-Looking Statements Some of the statements included in the documents filed herewith may be fo…
Regulation FD Disclosure. Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a January 20, 2026 Notice of Change and Modifications of Class E Common Stock Purchase Warrants and a January 20, 2026 Notice of Change and Modifications of Class F Common Stock Purchase Warrants that were sent to the holders of these warrants. The information, including Exhibits 99.1 and 99.2 referenced herein, are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities…
Regulation FD Disclosure. Furnished herewith as Exhibit 99.1 is AIM’s January 2026 Corporate Presentation. The information, including Exhibit 99.1 referenced herein, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Information set forth in
Entry into a material definitive agreement. On November 18, 2025, AIM ImmunoTech Inc. (the “Company”, “we”, “us” or “our”) entered into a Note Purchase Agreement (the “ Note Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”) and consummated the sale to such Investor of an unsecured Promissory Note (the “ Note ”) with an original principal amount of $3,301,250 in a private placement (the “ Private Placement ”) that closed on November 18, 2025. The Note carries an original…
Entry into a Material Definitive Agreement Filed herewith as Exhibit 3.1(i) is the Company’s Certificate of Incorporation as amended and restated through the date here. Exhibit 3.1(i) supersedes all individual Exhibits that contain pieces thereof.
Regulation FD Disclosure. Furnished herewith as Exhibit 99.1 is a presentation titled Maxim Growth Summit 2025 Presentation . We will be participating at the Maxim Growth Summit 2025, taking place October 22-23, 2025 in New York, NY. The presentation will be used at this event. The information, including Exhibit 99.1 referenced herein, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabi…
Other Events On July 31, 2025, the Company announced the closing of its previously announced public offering of an aggregate of 2,000,000 shares of its common stock (or pre-funded warrants in lieu thereof), Class E warrants to purchase up to 2,000,000 shares of common stock, and Class F warrants to purchase up to 2,000,000 shares of common stock, at a combined public offering price of $4.00 per share (or $3.999 per pre-funded warrant) and accompanying warrants. The warrants will have an exerc…
Entry into a Material Definitive Agreement The following agreements, previously filed as exhibits to the Registration Statement on Form S-1 (SEC File No. 333-284443) (the Registration Statement”) by AIM ImmunoTech Inc. (the “Company”) have been revised, are superseded by and are filed herewith as Exhibits 1.1, 4.26, 4.27, 4.28 and 10.63, respectively, and are incorporated by reference herein: the Placement Agency Agreement with Maxim Group LLC; the form of Class E/F Warrants; the form of Pre-…
Other Events On July 28, 2025, AIM ImmunoTech Inc. (the “Company”) reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating its drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX (the “DURIPANC” study). For more information, please see the July 28, 2025 press release which is attached to this Cur…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On June 17, 2025, AIM ImmunoTech Inc. (the “Company”) received a warning notification (the “Letter”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of $4.0 million or mo…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.